Sophia Sun
Optometrist · Pacifica, CANPI 1093291452
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.4% of the total across 174 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 13.0% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 174 payments — averaging $28.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$654
- Oyster Point Pharma, Inc.$544
- Bausch & Lomb Americas Inc.$544
- Alcon$419
- AbbVie$419
- Novartis$250
- plus $2K from 24 others
What the payments were for
- Speaking & faculty fees$261%
- Food & beverage$4,95098%
- Gifts$561%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 24 | $654 |
| Oyster Point Pharma, Inc. | 15 | $544 |
| Bausch & Lomb Americas Inc. | 13 | $544 |
| Alcon | 10 | $419 |
| AbbVie(2 entities) | 10 | $419 |
| Novartis | 21 | $250 |
| Iovance Biotherapeutics, Inc. | 1 | $237 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $237 |
| Dompe US, Inc. | 7 | $201 |
| Johnson & Johnson Vision Care, Inc. | 7 | $166 |
| Sight Sciences, Inc. | 6 | $151 |
| Eyevance Pharmaceuticals LLC | 7 | $131 |
| Biotissue Holdings Inc. | 4 | $122 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $115 |
| Coopervision Inc. | 4 | $114 |
| Kala Pharmaceuticals, Inc. | 5 | $90 |
| Tarsus Pharmaceuticals, Inc. | 3 | $87 |
| Optovue, Inc. | 1 | $73 |
| Mallinckrodt Hospital Products Inc. | 3 | $68 |
| Amgen(2 entities) | 3 | $65 |
| Rxsight Inc | 3 | $57 |
| Carl Zeiss Meditec, Inc. | 2 | $54 |
| Aerie Pharmaceuticals, Inc. | 2 | $40 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Thea Pharma Inc. | 2 | $36 |
| Optos, Inc. | 1 | $28 |
| ABB Con-cise Optical Group LLC | 1 | $23 |
| Alcon Research LLC | 1 | $23 |
| Harrow Eye, LLC | 1 | $22 |
| Shire North American Group Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,032 in reported general payments places this provider in the 90th percentile of 6,778 optometrist providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 33 | $41,503 |
| XiidraLifitegrast | 21 | $38,535 |
| Cyclosporine | 40 | $20,237 |
| CequaCyclosporine | 12 | $12,894 |
| MieboPerfluorohexyloctane/Pf | 16 | $11,908 |
| LumiganBimatoprost | 16 | $10,178 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $5,417 |
| Travoprost | 17 | $5,416 |
| Brimonidine Tartrate | 30 | $3,706 |
| Prednisolone Acetate | 82 | $3,230 |
| Latanoprost | 230 | $2,714 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 23 | $2,505 |
| Difluprednate | 18 | $1,641 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 27 | $1,326 |
| Timolol Maleate | 84 | $1,049 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $419 | $57,09765 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $544 | $50,44337 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $654 | $12,89412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,778 optometrist providers in California.
Other optometrist in Pacifica
- Steve YoelinNewport Beach$4.1M
- Matthew GellerSpring Valley$3.5M
- Melissa EricksonDavis$522K
- Omid KhodaiLake Forest$499K
- Jason TuSan Diego$351K
- Scott SchachterPismo Beach$312K
- Alicia LauSan Diego$300K
- Vin DangBakersfield$284K
- Steven FerrucciSepulveda$272K
- Katie ChuRosemead$271K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.